ATE324905T1 - Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall - Google Patents

Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Info

Publication number
ATE324905T1
ATE324905T1 AT01902406T AT01902406T ATE324905T1 AT E324905 T1 ATE324905 T1 AT E324905T1 AT 01902406 T AT01902406 T AT 01902406T AT 01902406 T AT01902406 T AT 01902406T AT E324905 T1 ATE324905 T1 AT E324905T1
Authority
AT
Austria
Prior art keywords
stroke
schaemia
plgf
treat
prevent
Prior art date
Application number
AT01902406T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Original Assignee
D Collen Res Foundation Vzw
Flanders Interuniversity Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by D Collen Res Foundation Vzw, Flanders Interuniversity Inst filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of ATE324905T1 publication Critical patent/ATE324905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Clamps And Clips (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
AT01902406T 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall ATE324905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
US23659400P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
ATE324905T1 true ATE324905T1 (de) 2006-06-15

Family

ID=26243563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902406T ATE324905T1 (de) 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Country Status (9)

Country Link
EP (1) EP1253935B1 (de)
JP (1) JP4969753B2 (de)
AT (1) ATE324905T1 (de)
AU (2) AU4643501A (de)
DE (1) DE60119285T2 (de)
DK (1) DK1253935T3 (de)
ES (1) ES2263582T3 (de)
PT (1) PT1253935E (de)
WO (2) WO2001057181A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
ATE378056T1 (de) * 2001-08-10 2007-11-15 Imclone Systems Inc Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
DE50309809D1 (de) 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
EP2295449A1 (de) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimerer Form
WO2014117155A1 (en) * 2013-01-28 2014-07-31 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
JP2001524828A (ja) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
EP1053326A2 (de) * 1998-02-06 2000-11-22 Collateral Therapeutics Varianten des angiogenen faktors vaskularer endothelialzell-wachstumsfaktor: vegf

Also Published As

Publication number Publication date
DK1253935T3 (da) 2006-09-04
JP4969753B2 (ja) 2012-07-04
WO2001057181A2 (en) 2001-08-09
WO2001056593A3 (en) 2002-04-25
EP1253935A2 (de) 2002-11-06
EP1253935B1 (de) 2006-05-03
DE60119285D1 (de) 2006-06-08
ES2263582T3 (es) 2006-12-16
AU4643501A (en) 2001-08-14
JP2003521522A (ja) 2003-07-15
WO2001056593A2 (en) 2001-08-09
DE60119285T2 (de) 2007-05-10
PT1253935E (pt) 2006-08-31
AU2001230243A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MEP8209A (en) Modified factor viii
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ATE254461T1 (de) Behandlung von augenschmerzen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
TR200200278T2 (tr) Kalsilitik bileşimler
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20026286D0 (no) Nye peptider
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253935

Country of ref document: EP